Mesenchymal Stromal Cells Modulate Monocytes Trafficking in Coxsackievirus B3-Induced Myocarditis

KAPRA MITEVA,a,b KATHLEEN PAPPRITZ,a,b MUHAMMAD EL-SHAFeey,a FENGQUAN DONG,a Jochen Ringe,a,c CARSTEN TSCHOPE,a,b,d SOPHIE VAN LINHTHOUTa,b,d

Key Words. Myocarditis • Mesenchymal stromal cells • Monocytes trafficking

Mesenchymal stromal cell (MSC) application in Coxsackievirus B3 (CVB3)-induced myocarditis reduces myocardial inflammation and fibrosis, exerts prominent extra-cardiac immunomodulatory, and improves heart function. Although the abovementioned findings demonstrate the benefit of MSC application, the mechanism of the MSC immunomodulatory effects leading to a final cardioprotective outcome in viral myocarditis remains poorly understood. Monocytes are known to be a trigger of myocardial tissue inflammation. The present study aims at investigating the direct effect of MSC on the mobilization and trafficking of monocytes to the heart in CVB3-induced myocarditis.

One day post CVB3 infection, C57BL/6 mice were intravenously injected with 1 x 10⁶ MSC and sacrificed 6 days later for molecular biology and flow cytometry analysis. MSC application reduced the severity of myocarditis, and heart and blood pro-inflammatory Ly6Chigh and Ly6Cmiddle monocytes, while those were retained in the spleen. Anti-inflammatory Ly6Clow monocytes increased in the heart, blood, and spleen of MSC-treated CVB3 mice. CVB3 infection induced splenic myelopoiesis, while MSC application slightly diminished the spleen myelopoietic activity in CVB3 mice. Left ventricular (LV) mRNA expression of the chemokines monocyte chemotactic protein-1 (MCP)-1, MCP-3, CCL5, the chemokines monocyte chemotactic protein-1, MCP-3, CCL5, the adhesion molecules intercellular adhesion molecule-1, vascular cell adhesion molecule-1, the pro-inflammatory cytokines interleukin-6, interleukin-12, tumor necrosis factor-α, the pro-fibrotic transforming growth factor-β, and circulating MCP-1 and MCP-3 levels decreased in CVB3 MSC mice, while LV stromal cell-derived factor-1α mRNA expression and systemic levels of fractalkine were increased in CVB3 MSC mice. MSC application in CVB3-induced myocarditis modulates monocytes trafficking to the heart and could be a promising strategy for the resolution of cardiac inflammation and prevention of the disease progression.

INTRODUCTION

Inflammation is a major trigger and a dominant mechanism in the pathogenesis of inflammatory cardiomyopathy and heart failure, evident by the finding that extensive inflammation in patients with acute myocarditis is an independent predictor of a poor outcome [1].

The immune and inflammatory cell network is emerging as a major inducer of immune cell-mediated cardiac injury, which is associated with extreme changes of the mononuclear phagocyte network of the failing heart, spleen, peripheral blood, and bone marrow [2]. In heart failure, the splenic microenvironment plays a major role in the activation and trafficking of innate immune cells to the heart where they induce immune cell-mediated injury. Monocytes and macrophages have been recognized as key effector cells after myocardial infarction and in myocarditis [3], comprising a major proportion of the heart infiltrating cells and playing a leading role in the pathogenesis [4, 5]. Monocytes are a heterogeneous multifunctional cellular population, of which CD11b⁺CD11c⁻Ly6ClowCCR2⁺CX3CR1low and CD11b⁺CD11c⁻Ly6CmidCCR2⁺CX3CR1low...
cells infiltrate to sites of inflammation in response to chemokine signals and differentiate into inflammatory M1 macrophages secreting pro-inflammatory cytokine, such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) and contribute to tissue degradation and T cell activation [6]. In contrast, the CD11b+ Ly6C(low)CCR2(low)CX3CR1(high) monocytes are recruited to the inflamed tissue and are more likely to differentiate into M2 macrophages, which secrete anti-inflammatory cytokines and contribute to tissue repair [6].

The chemokine system represents the main regulator of leukocyte recruitment [7], while the spleen, in addition to the blood, functions as a reservoir of monocytes outside the bone marrow. Monocytes are released from splenic reservoir, and Ly6C(high) monocytes are selectively recruited to the injured heart [8]. Monocyte chemotactic protein-1 (MCP-1/CCL2) and its receptor chemokine (C-C motif) receptor-2 (CCR2) play a leading role in the recruitment of monocytes/macrophages during inflammatory processes in the cardiovascular system [9]. Furthermore, MCP-1 and MCP-3 (also known as CCL7) are CC-chemokines that bind to CCR2 and mediate Ly6C(high) monocyte recruitment [8, 10, 11]. Ly6C(low) monocytes respond to CX3C-chemokine ligand 1 (CX3CL1; also known as fractalkine), which governs Ly6C(low) monocyte infiltration into the myocardium [11].

There is a growing body of preclinical and early clinical evidence showing great promise of mesenchymal stromal cell (MSC) therapy in the repair of damaged cardiac tissue [12–14]. We have demonstrated that MSC have the potential to treat acute coxsackievirus B3 (CVB3)-induced inflammatory cardiomyopathy since MSC cannot be infected with CVB3 and exert anti-viral effects [14]. Moreover, intravenous (i.v.) MSC application in CVB3-infected mice reduced CVB3-associated cardiomyopathy, myocardial fibrosis and inflammation, and induced prominent systemic immunomodulatory effects as indicated by the induction of IL-10 secreting regulatory T cells and increased CD4+ CD25+ FoxP3+ T cells in the spleen as well as in the circulation of CVB3 MSC mice [6–8, 15, 16]. The abovementioned findings clearly demonstrate that MSC application is not only safe and cardioprotective, but also associated with prominent extra-cardiac immunomodulatory effects in a model of CVB3-induced inflammatory cardiomyopathy.

However, the exact mechanism of the MSC-protective effects in viral myocarditis is still not completely understood. Since monocytes are known to be a marker and trigger of myocardial tissue inflammation [17], the aim of the present study is to evaluate the effect of i.v. MSC application on cardiac trafficking of monocytes in murine CVB3-induced myocarditis. This study could further give a deeper understanding of the immunomodulatory effects of MSC leading to a final cardioprotective outcome in viral myocarditis.

**Materials and Methods**

**Murine CVB3-Induced Myocarditis and Cell Application**

Eight-week-old male C57BL/6 (Charles Rivers, Wilmington, MA, USA) mice were infected by intraperitoneal injection of 1x10^7 plaque forming units (PFU) of CVB3 virus (Nancy strain). Control mice received PBS instead of CVB3. One day after CVB3 virus infection, 1 x 10^6 MSC of passage 5 were i.v. administrated via the tail vein into C57BL/6 mice. All mice were sacrificed on day seven post-CVB3 infection. The left ventricle (LV) was harvested and snap-frozen for molecular biology. For flow cytometry analysis, heart, blood, and spleen mononuclear cells (MNCs) were isolated. The investigation was approved by the ethical committee for the use of experimental animals of Charité-Medical University, Berlin (Nr:G0094/11) and was performed, in accordance with the principles of laboratory animal care and German animal protection law.

**MSC Isolation**

Human adult MSC were isolated from iliac crest bone marrow aspirates of eight healthy donors after their written approval according to Binger et al. [18]. MSC were cultured and expanded for injection in Dulbecco’s modified Eagle’s medium (Biochrom, Berlin, Germany) supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, 1% glutamine, 2% HEPES, and 2 ng/ml of basic fibroblast growth factor (Tebu-bio, Offenbach, Germany). Cultivated MSC were triple negative for the markers CD45, CD34, and CD11b, but stained positively for the markers CD73, CD29, CD105, CD106, CD90, and CD44.

**MNCs Isolation From Mouse Heart, Blood, and Spleen**

Cardiac MNCs were isolated from control PBS, control MSC, CVB3 and CVB3 MSC mice, 7 days postinfection using the Neonatal Heart Dissociation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) and gentleMACS Octo Dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany), according to the manufacturer’s instructions. Splenocytes were isolated from control PBS, control MSC, CVB3, and CVB3 MSC mice according to Van Lintshout et al. [16]. Blood MNCs were isolated from whole blood by density gradient centrifugation using Histopaque-1083 (Sigma, Steinheim, Germany). Heart, blood and spleen MNCs were used for the analysis of CD11b+Ly6C(high)CCR2(high)CX3CR1(low), CD11b+Ly6C(low)CCR2(high)CX3CR1(low), CD11b+Ly6C(high)CCR2(low)CX3CR1(high), and CD11b+Ly6C(low)CCR2(low)CX3CR1(high) monocytes.

**Flow Cytometry Analysis**

Flow cytometry analysis of heart, blood, and spleen MNCs was performed using the directly conjugated monoclonal mouse antibodies anti-CD11b Alexa488, anti-CD11b PerCP/Cy5.5, anti-Ly6C Brilliant Violet 421, anti-CX3CR1 PE and anti-CCR2 Alexa647 antibody. Spleen MNCs were stained with anti-mouse CD11c PerCP Cy5.5, anti-mouse F4/80 APC, anti-mouse vascular cell adhesion molecule (VCAM) PE, anti-mouse GM-CSF PE (Biolegend, San Diego, CA), anti-mouse CD4 Vio Blue and anti-mouse IL-3 APC (Miltenyi, Bergisch Gladbach, Germany). Surface staining was performed according to the manufacturer’s instructions. Sample analysis was performed on a MACSQuant Analyzer (Miltenyi Biotec, Bergisch Gladbach, Germany) and flow cytometry data were analyzed by FlowJo 8.7. software (FlowJo, LLC, OR). Supporting Information Figure 1 shows representative flow cytometry analysis of monocytes subsets according to Yang et al. [6].

**Gene Expression Analysis**

Frozen heart tissue was homogenized with an IKA T25D ULTRA TURRAX homogenizer (Laboratory equipment, Germany) in Trizol, followed by chloroform extraction and isopropanol precipitation. Next, RNA was DNase treated with the NucleoSpin RNA II Kit (Macherey-Nagel, Düren, Germany) and subsequently reverse transcribed via the High Capacity cDNA Reverse Transcription Kit from Applied Biosystems by Thermo Fisher Scientific (Carlsbad, CA, USA). To assess the mRNA expression of the target genes MCP-1, MCP-3, CCL5, stomatal cell-derived factor-1α (SDF-1α), IL-6, IL-12, TNF-α, transforming growth factor-β (TGF-
Figure 1.

A. Pro-inflammatory monocytes

B. Anti-inflammatory monocytes

C. Anti-inflammatory monocytes

D. Anti-inflammatory monocytes
MSCs Decrease the CVB3-Induced Pro-Inflammatory Monocyte Subsets, While Promoting Anti-Inflammatory Monocytes in the Heart

To evaluate the impact of MSC on the cardiac infiltrating monocyte subsets in CVB3-induced myocarditis, flow cytometry analysis of the pro- and anti-inflammatory monocyte subsets was performed. The analysis revealed a 3.4-fold \((p < .0001)\) and 2.4-fold \((p < .0001)\) increase in the percentage of pro-inflammatory Ly6C\textsuperscript{high} and Ly6C\textsubscript{middle} monocytes defined as CD11b\textsuperscript{+} Ly6C\textsuperscript{high}CCR2\textsuperscript{high}CX3CR1\textsuperscript{low} and CD11b\textsuperscript{+} Ly6C\textsubscript{middle}CCR2\textsuperscript{high}CX3CR1\textsuperscript{low}, respectively, in CVB3-infected versus control mice.

Supporting Information

Figure 1 illustrates the gating strategy in detail. In contrast, MSC application reduced the percentage of Ly6C\textsuperscript{high} and Ly6C\textsubscript{middle} monocytes in the heart by 2.4-fold \((p < .0001)\) and 2-fold \((p < .0001)\) compared to CVB3 mice, respectively, suggesting a decreased influx of pro-inflammatory monocytes to the heart after i.v. injection of MSC (Fig. 1A, 1B). With respect to the anti-inflammatory monocyte-subset CD11b\textsuperscript{+} Ly6C\textsuperscript{low}CCR2\textsuperscript{low}CX3CR1\textsuperscript{high}, MSC-treated CVB3 mice exhibited a 2.5-fold \((p < .05)\) higher percentage of anti-inflammatory Ly6C\textsuperscript{low} monocytes in the heart versus CVB3 mice (Fig. 1C, 1D).

MSCs Modulate the Monocyte Subsets in the Blood of CVB3-Infected Mice

To understand how MSC affect the pro- and anti-inflammatory monocytes trafficking to the heart, monocyte subsets were analyzed in the blood. In accordance with the observed induction of pro-inflammatory monocyte subsets in the heart of CVB3-infected mice, the percentages of pro-inflammatory Ly6C\textsuperscript{high} and Ly6C\textsubscript{middle} monocytes were elevated by 13.2-fold \((p < .01)\) in CVB3-infected mice in comparison to control mice, respectively (Fig. 2A, 2B). Consistent with the observations in the heart of CVB3 MSC treated mice, the percentages of the pro-inflammatory Ly6C\textsuperscript{high} and Ly6C\textsubscript{middle} monocytes declined by 5.4-fold \((p < .0001)\) and 2.6-fold \((p < .01)\), respectively, while the percentage of circulating anti-inflammatory monocytes increased by 2.4-fold \((p < .01)\), compared to CVB3 mice (Fig. 2C, 2D).

**Statistical Analysis**

Statistical analysis was performed using Prism 6 for Mac OS X (GraphPad Software, Inc., La Jolla). Ordinary one-way ANOVA was used for statistical analysis of the data with correction for multiple comparisons via the Tukey test. Data are presented as mean ± SEM. Differences were considered to be significant when the two-sided \(p\) value was lower than .05.
Figure 2.

A. Pro-inflammatory monocytes

B. Anti-inflammatory monocytes

C. Control

D. CVB3

** Figure 2. **
MSCs Retain Pro-Inflammatory Monocyte Subset in the Spleen, While Inducing Anti-Inflammatory Ly6C<sub>low</sub> Monocytes

Given the importance of the spleen as a monocytes reservoir, by which splenic monocytes are recruited to the heart upon cardiac injury [8], we next evaluated the percentage of pro-inflammatory and anti-inflammatory monocytes in the spleen of CVB3 mice and the impact of MSC administration on splenic monocyte subsets [2]. The percentage of pro-inflammatory Ly6C<sup>high</sup> and Ly6C<sub>middle</sub> monocytes in CVB3-infected mice was augmented by 1.9-fold (<i>p</i> < .01) and 2.1-fold (<i>p</i> < .05), respectively, in comparison to control mice (Fig. 3A). Interestingly, the presence of pro-inflammatory Ly6C<sup>high</sup> and Ly6C<sub>middle</sub> monocytes was 1.5-fold (<i>p</i> < .05) higher in the spleen of MSC-treated CVB3 mice compared to CVB3 mice and 1.4-fold (<i>p</i> < .05) higher versus control mice. In addition, a higher migration potential of splenic MNCs derived from CVB3 mice compared to MNCs derived from CVB3 MSC mice was evident in a spreading assay performed on a rmVCAM-1 matrix (Fig. 3C, 3D). Cells, which exhibited flattened morphology and lamellipodia were considered positive for spreading. With respect to Ly6C<sub>low</sub> monocytes, CVB3 MSC mice exhibited a 1.9-fold (<i>p</i> < .01) higher percentage of anti-inflammatory Ly6C<sub>low</sub> monocytes in the spleen in comparison to CVB3 mice (Fig. 3B).

MSCs Slightly Modulate Splenic Extramedullary Myelopoiesis

VCAM-1<sup>+</sup> macrophages in the splenic red pulp are essential for the extramedullary myelopoiesis and increase the systemic levels of inflammatory leukocytes [19]. To investigate the role of splenic extramedullary myelopoiesis in CVB3-induced myocarditis in mice and to further understand the mechanism of the MSC-mediated effects in the spleen, the percentage of splenic CD11b<sup>+</sup>F4/80<sup>+</sup>Ly6C<sup>VCAM</sup><sup>+</sup> macrophages was evaluated. CVB3 infection resulted in a 1.5-fold (<i>p</i> < .0001) higher percentage of splenic VCAM<sup>+</sup> macrophages, while MSC application in CVB3 mice did not have any effect on the percentage of splenic CD11b<sup>+</sup>F4/80<sup>+</sup>Ly6C<sup>VCAM</sup><sup>+</sup> macrophages (Fig. 3E). Myelopoiesis is also positively regulated by splenic CD4<sup>+</sup> T cells that produce myelopoietic cytokines GM-CSF and IL-3 [20]. Therefore, we next examined the frequencies of CD4<sup>+</sup>GM-CSF<sup>+</sup> and CD4<sup>+</sup>IL-3<sup>+</sup> cells in the spleen of control, control MSC, CVB3, and CVB3 MSC mice. CVB3 infection or MSC treatment of CVB3 mice did not affect CD4<sup>+</sup> cells producing the myelopoietic cytokine GM-CSF<sup>+</sup> (Fig. 3F). However, the frequency of CD4<sup>+</sup>IL-3<sup>+</sup> cells increased by 2-fold (<i>p</i> < .05) (Fig. 3G) in CVB3-infected versus control mice, while CVB3 MSC mice exhibited a 2.4-fold (<i>p</i> < .01) lower percentage of CD4<sup>+</sup>IL-3<sup>+</sup> cells.

MSCs Regulate the Trafficking of Monocyte Subsets Through Chemokines Modulation

Considering the importance of chemokines for the recruitment of monocytes [10, 21], mRNA expression of the chemokines MCP-1, MCP-3, and CCR5, associated with the infiltration of pro-inflammatory monocytes, was analyzed in the heart. CVB3-infection led to a 90.5-fold (<i>p</i> < .0001), 124.3-fold (<i>p</i> < .0001) and 99.5-fold (<i>p</i> < .0001) higher LV mRNA expression of MCP-1 (Fig. 4A), MCP-3 (Fig. 4B), as well as of CCR5 (Fig. 4C) versus control mice, respectively. In contrast, CVB3-infected mice treated with MSC showed prominent reduction by 51.4-fold (<i>p</i> < .0001), 225-fold (<i>p</i> < .0001), and 71.8-fold (<i>p</i> < .0001) of LV MCP-1, MCP-3, and CCL5 chemokine expression, respectively, whereas, MSC application in CVB3 mice induced a 3.4-fold (<i>p</i> < .0001 vs. CVB3 mice) higher expression of SDF-1α (Fig. 4D), known to attract cardiac-reparative monocytes. To investigate whether the cardiac chemokines expression pattern corresponds with the systemic chemokine levels, MCP-1, MCP-3, SDF-1α, and CX3CR1 were evaluated in the serum. A similar trend of chemokine pattern was observed in the serum, CVB3 infection augmented the serum levels of MCP-1 and MCP-3 by 3.9-fold (<i>p</i> < .0001) and 3.2-fold (<i>p</i> < .0001), respectively, in comparison to control mice, whereas CVB3 MSC mice manifested 3.2-fold (<i>p</i> < .0001) and 2.6-fold (<i>p</i> < .01) lower MCP-1 and MCP-3 serum levels, respectively, compared to CVB3 mice (Fig. 5A, 5B). The detected SDF-1α did not differ among the groups, but importantly, MSC application in CVB3 mice resulted in 1.4-fold (<i>p</i> < .01 vs. CVB3 mice) higher serum levels of CX3CL1/Fractalkine (Fig. 5C, 5D).

MSCs Abrogate Cardiac Adhesion Molecules Expression in CVB3-Infected Mice

Expression of adhesion molecules such as ICAM-1 and VCAM-1 on endothelial cells promotes leucocyte migration via direct binding to leucocyte cell surface receptors, firm adhesion and guidance of monocyte homing into the inflamed tissue [6, 22, 23]. Taking the importance of adhesion molecules expression for monocytes adhesion and infiltration into account, LV VCAM-1 and ICAM-1 expression was evaluated. As expected, CVB3 infection magnified the LV VCAM-1 and ICAM-1 expression by 6.3-fold (<i>p</i> < .0001) and 6.8-fold (<i>p</i> < .0001), respectively, in comparison to control mice (Fig. 6A, 6B), while CVB3 MSC mice exhibited 11.7-fold (<i>p</i> < .0001) and 5.1-fold (<i>p</i> < .0001) lower expression of VCAM-1 and ICAM-1 versus CVB3 mice, respectively.

MSCs Diminish the Expression of Cardiac Pro-Inflammatory Cytokines and the Pro-Fibrotic Cytokine TGF-β1 in CVB3-Infected Mice

To evaluate whether the observed modulation of pro-inflammatory monocytes in the heart of CVB3 mice upon MSC application did not differ among the groups, but importantly, MSC application in CVB3 mice resulted in 1.4-fold (<i>p</i> < .01 vs. CVB3 mice) higher serum levels of CX3CL1/Fractalkine (Fig. 5C, 5D).

Figure 2. (See prior page) MSCs modulate monocyte subsets in the blood of coxsackievirus B3-infected mice. (A): Bar graphs represent the mean ± SEM of CD11b<sup>+</sup>CD11c<sup>+</sup>Ly6C<sup>high</sup>CCR2<sup>high</sup>CX3CR1<sup>low</sup> and CD11b<sup>+</sup>CD11c<sup>+</sup>Ly6C<sub>middle</sub>CCR2<sub>high</sub>CX3CR1<sub>low</sub> positive cells in the blood of control mice (open bar) and CVB3-infected mice (closed bar) injected with PBS or MSC, expressed as the percentage of Ly6C<sub>high</sub> and Ly6C<sub>middle</sub> positive cells, respectively, with n = 8–9 per group and **, <i>p</i> < .01; ***, <i>p</i> < .001. (B): The panel represents dot plots of blood of CD11b<sup>+</sup>CD11c<sup>+</sup>Ly6C<sup>high</sup>CCR2<sup>high</sup>CX3CR1<sup>low</sup> and CD11b<sup>+</sup>CD11c<sup>+</sup>Ly6C<sub>middle</sub>CCR2<sub>high</sub>CX3CR1<sub>low</sub> positive cells as percentage of Ly6C<sub>high</sub> or Ly6C<sub>middle</sub> cells, as indicated. (C): Bar graphs represent the mean ± SEM of CD11b<sup>+</sup>CD11c<sup>+</sup>Ly6C<sup>low</sup>CCR2<sup>low</sup>CX3CR1<sup>high</sup> positive cells in the blood of control mice (open bar) and CVB3-infected mice (closed bar) injected with PBS or MSC, expressed as the percentage of Ly6C<sub>low</sub> positive cells with n = 8–9 per group and **, <i>p</i> < .01. (D): The panel represents dot plots of blood anti-inflammatory CD11b<sup>+</sup>Ly6C<sup>low</sup>CCR2<sup>low</sup>CX3CR1<sup>high</sup> positive cells as the percentage of Ly6C<sub>low</sub> cells, as indicated. Abbreviations: CCR2, chemokine (C-C motif) receptor-2; CVB3, coxsackievirus B3; CX3CL1, chemokine (C-X-C motif) ligand-1; MSC, mesenchymal stromal cell.

© 2017 The Authors Stem Cells Translational Medicine published by STEM CELLS Translational Medicine
Figure 3. MSCs retain pro-inflammatory monocytes subsets in the spleen, induce anti-inflammatory monocytes and slightly affect the spleen extramedullary myelopoiesis in coxsackievirus B3-infected myocarditis. (A): Bar graphs represent the mean ± SEM of CD115^+CD11b^+Ly6C^highCCR2^highCX3CR1^low and CD115^+CD11b^+Ly6C^middleCCR2^highCX3CR1^low positive cells in the spleen of control mice (open bar) and CVB3-infected mice (closed bar) injected with PBS or MSC, expressed as the percentage of Ly6C^high and Ly6C^middle positive cells, respectively with n = 8–9 per group and *, p < .05; **, p < .01; ***, p < .001. (B): Bar graphs represent the mean ± SEM of CD115^+CD11b^+Ly6C^lowCCR2^lowCX3CR1^high positive cells in the spleen of control mice (open bar) and CVB3-infected mice (closed bar) injected with PBS or MSC, expressed as percentage of Ly6C^low positive cells with n = 8–9 per group and **, p < .01; ***, p < .001. (C): Phase contrast pictures of spleen mononuclear cell (MNCs) derived from control mice and CVB3-infected mice injected with PBS or MSC, at ×100 magnification. Cells with flat morphology were considered positive for spreading. (D): Phalloidining staining of spleen MNCs derived from control mice and CVB3-infected mice injected with PBS or MSCs, at ×100 magnification. Cells showing lamellipodia were considered positive for spreading. (E): Bar graphs represent the mean ± SEM of VCAM^+ macrophages in the spleen of control mice (open bar) and CVB3-infected mice (closed bar) injected with PBS or MSC, expressed as the percentage of Ly6C^high positive cells, with n = 8–9 per group and *, p < .05; **, p < .01; ***, p < .001. (F): Bar graphs represent the mean ± SEM of CD4^+GM-CSF^+ in the spleen of control mice (open bar) and CVB3-infected mice (closed bar) injected with PBS or MSC, expressed as the percentage of total mononuclear cells (MNCs), with n = 5–6 per group and **, p < .01. (G): Bar graphs represent the mean ± SEM of CD4^+IL-3^+ in the spleen of control mice (open bar) and CVB3-infected mice (closed bar) injected with PBS or MSC, expressed as the percentage of total MNCs, with n = 5–6 per group and *, p < .05; **, p < .01. Abbreviations: CCR2, chemokine (C-C motif) receptor-2; CVB3, coxsackievirus B3; CX3CR1, chemokine (C-X3-C motif) receptor-1; MSC, mesenchymal stromal cell; VCAM-1, vascular cell adhesion molecule-1.
application corresponds with a modulation in cytokine expression, LV mRNA expression of IL-6, IL-12, TNF-α known to be released by Ly6Chigh monocytes [24–27] and by inflammatory M1 macrophages was analyzed. CVB3 mice exhibited 30.1-fold (p < .005), 18.8-fold (p < .0001), 5.7-fold (p < .0001) and 4.8-fold (p < .01) upregulated LV mRNA expression of IL-6, TNF-α, IL-12 and TGF-β1 (Fig. 6C-6F), in comparison to control mice, respectively. MSC treatment of CVB3-infected mice downregulated the LV mRNA expression of the pro-inflammatory cytokines IL-6, TNF-α, IL-12, and the pro-fibrotic cytokine TGF-β1 by 86.8-fold (p < .01), 30.4-fold (p < .0001), 7.4-fold (p < .0001) and 5.6-fold (p < .01), respectively, compared to CVB3 mice.

**MSCs Reduce the Severity of Myocarditis**

Histological sections were stained with hematoxylin/eosin to estimate the extent of myocardial damage. The pathological score of myocardial damage was significantly higher in the PBS- injected CVB3 mice compared to the MSC-treated CVB3 mice, which displayed a reduced size of inflammatory foci (Fig. 6G, 6H).

**DISCUSSION**

The salient finding of the present study is that i.v. MSC application diminishes trafficking of pro-inflammatory monocyte subsets, promotes the migration of anti-inflammatory monocytes toward the heart in CVB3 myocarditis mice via modulation of the local and systemic chemokine pattern, and only mildly affects the splenic myelopoiesis.

Myocarditis is characterized by a complex manifestation and pathogenesis associated with a profound inflammatory destruction of the myocardium [25]. However, several clinical trials applying immunosuppressive treatment strategies have been largely disappointing [28–30] emphasizing the need for immunomodulatory therapies which could more selectively target the disease. Our previous studies demonstrated that MSC application in CVB3-infected mice is safe, leads to anti-apoptotic and anti-fibrotic effects, reduces myocardial inflammation, and induces prominent systemic immunomodulation without compromising the virus clearance, which is all translated into improved heart function [15, 16, 31]. MSC migrate to injured tissues and rapidly disappear after
systemic infusion [32, 33] and mediate protective effects without a permanent engraftment [15, 34]. Despite the limited engraftment, long-lasting effects of MSC have thus been proposed to be mediated via paracrine secretion of soluble factors or microvesicles, such as exosomes [35]. Factors present at the inflammatory site are critical determinants of the immunosuppressive activity of MSCs [16, 36], which includes inhibition of immune cells activation, suppression of pro-inflammatory cytokines secretion by activated immune cells, and impairment of the immune cells migratory potential through inhibition of the adhesion molecules and receptors that are responsible for immune cell trafficking [37, 38]. MSC mediate immunosuppression via secretion of soluble molecules and cytokines like indoleamine 2,3-dioxygenase, prostaglandin E2, TGF-β, hepatocyte growth factor, interleukin-10, and human leukocyte antigen-G [39]. Moreover, MSC have been shown to directly act on monocytes and induce an immunomodulatory phenotype through the secretion of HGF and potentially factors downstream of the COX2 pathway [40, 41].

Considering the role of monocytes as a marker of myocardial tissue inflammation [17], and a trigger of disease progression on the one hand, and the immunomodulatory properties of MSC on the other hand, we investigated the potential of MSC to specifically regulate the pro- as well as anti-inflammatory monocyte subsets in a model of CVB3-induced myocarditis.

Systemic monocytosis occurs as a result of an acute or a chronic inflammation, where monocytes are recruited to the inflammatory site to exacerbate the immune activation and inflict tissue damage or to support inflammation resolution [42]. Ly6Chigh monocytes are rapidly recruited to the heart and initially exert beneficial effects [6, 42, 43]. However, their persistence is deleterious [44, 45], while Ly6Clip monocytes have anti-inflammatory properties supporting healing [6, 46]. Monocytes/macrophages are known to be specifically involved in CVB3-induced myocarditis by maintaining a chronic inflammatory response [47]. In agreement, the present study demonstrates the induction of pro-inflammatory monocyte subsets in the heart, blood, and spleen upon CVB3-infection, which was associated with a profound cardiac expression of inflammatory cytokines and chemokines, and cardiac damage. MSC application in CVB3-infected mice diminished the infiltration of pro-inflammatory monocyte subsets toward the heart and induced

**Figure 5.** Mesenchymal stromal cells regulate systemic chemokines levels in Coxsackievirus B3-infected myocarditis mice. Bar graphs represent the mean ± SEM of serum (A) MCP-1 (pg/ml), (B) MCP-3 (pg/ml), (C) SDF-1α (ng/ml) and (D) CX3CL1/Fractalkine (ng/ml) levels of control, CVB3, control MSC, and CVB3 MSC mice, with n = 4–6 per group and *, p < .05; **, p < .01; ***, p < .001. Abbreviations: CVB3, Coxsackievirus B3; CX3CL1, chemokine (C-X3-C motif) ligand-1; MCP, monocyte chemotactic protein; MSC, mesenchymal stromal cell; SDF-1α, stromal cell-derived factor-1α.
Ly6C<sup>low</sup> monocytes associated with tissue repair, leading to less severe myocarditis [6, 46]. In contrast to the decreased Ly6C<sup>high</sup> monocytes in the heart and blood after MSC application, the percentage of Ly6C<sup>high</sup> and Ly6C<sup>middle</sup> monocytes was higher in the spleen of CVB3 MSC compared to CVB3 mice. The following observation suggests that MSC retained the pro-inflammatory monocytes in the spleen and used it as a site for storage, decreasing the mobilization of inflammatory monocytes from the spleen, their emigration to the blood and subsequent accumulation into the heart, limiting further immune-mediated cardiac injury. In line with this hypothesis, the spreading and lamellipodia of CVB3 MSC-derived splenocytes was decreased in comparison to splenocytes from CVB3 mice, indicating that MSC abrogate the migration potential of splenic MNCs.

**Figure 6.** MSCs application abrogates left ventricular expression of adhesion molecules, pro-inflammatory cytokines and the pro-fibrotic cytokine TGF-β1 in coxsackievirus B3-infected mice and improves the pathologic myocarditis score. Bar graphs represent the mean ± SEM of (A) VCAM-1 and (B) ICAM-1, (C) IL-6, (D) TNF-α, (E) IL-12, and (F) TGF-β1 mRNA expression in the LV of control, CVB3, control MSC, and CVB3 MSC mice, as indicated, with n = 5–6 per group and **, p < .01 and ***, p < .001 (G) Bar graphs represent the mean ± SEM of the pathologic score of myocarditis assessed by hematoxylin/eosin staining of control, CVB3, control MSC, and CVB3 MSC mice, as indicated, with n = 4–5 per group and *, p < .05. (H): Hematoxylin/eosin-stained heart sections of control mice receiving PBS (upper left panel) or MSC (upper right panel), or of CVB3 infected mice receiving PBS (lower left panel) or MSC (lower right panel), at a magnification of ×100. Abbreviations: CVB3, coxsackievirus B3; CX3CL1, chemokine (C-X3-C motif) ligand-1; ICAM-1, intercellular adhesion molecule-1; IL, interleukin; MSC, mesenchymal stromal cell; TGF-β1, transforming growth factor-β1; TNF-α, tumor necrosis factor-α; VCAM-1, vascular cell adhesion molecule-1.
With respect to the increased presence of pro-inflammatory monocytes in the spleen upon CVB3 infection, we speculate that this is due to the still active generation of monocytes in the spleen at this stage of the inflammatory process or due to postviral sensitization of the immune system, knowing that the spleen is a target of CVB3 infection [48]. In parallel, MSC application increased systemic levels of fractalkine, raising the deployment of anti-inflammatory monocytes to the heart. Finally, MSC retained the pro-inflammatory monocyte subsets in the spleen, preventing their mobilization, emigration to the blood and accumulation in the heart, limiting further immune-mediated cardiac injury and promoted spleen anti-inflammatory monocytes. Abbreviations: CCR2, chemokine (C-C motif) receptor-2; CVB3, coxsackievirus B3; CX3CL1, chemokine (C-X3-C motif) ligand-1; ICAM-1, intercellular adhesion molecule-1; Il, interleukin; MCP, monocyte chemotactic protein; MSC, mesenchymal stromal cell; TGF-β1, transforming growth factor-β1; TNF-α, tumor necrosis factor-α; VCAM-1, vascular cell adhesion molecule-1.

Leukocytes trafficking is mainly regulated by the chemokine system [7]. CVB3 infection stimulates the expression of MCP-1 in myocardial cells, which subsequently leads to the migration of MNCs [21]. CCR2 and MCP-1/MCP-3 are critical for monocyte mobilization and particularly Ly6G<sup>high</sup> monocyte recruitment to the injured heart [8, 10], while Ly6C<sup>low</sup> monocytes respond to CX3CL1 guiding their infiltration into the myocardium [11]. CCL5 (RANTES) expression is highly upregulated during infection/inflammation and is also important for the trafficking of Ly6G<sup>high</sup> monocytes expressing its ligand CCR5 [49]. SDF-1α is known to mediate cardioprotection through mobilization of stem cells, cardiac myocyte survival, heart regeneration [50] and through the recruitment of anti-inflammatory monocytes enhancing the remodeling of the microvascular network [51]. MSC application suppressed the viral-induced cardiac expression of the chemokines MCP-1, MCP-3, and CCL5 recruiting inflammatory monocytes within inflamed tissues [10, 49]. In parallel, MSC induced SDF-1α expression in the heart of CVB3-infected mice.

Besides modulating the cardiac chemokine pattern, MSC modulated the systemic chemokine levels, reducing the CVB3-increased circulating levels of MCP-1 and MCP-3, while promoting the increase in circulating CX3CL1 levels, which regulate the trafficking and mobilization of Ly6C<sup>low</sup> monocytes into the myocardium [11].

The inflammatory response is dependent on the activation of adhesive interactions between endothelial cells and leukocytes. In this regard, our data reveal that MSC abrogates the CVB3-induced expression of the adhesion molecules ICAM-1 and VCAM-1, resulting in a blocked adhesion and transmigration into the inflamed tissue of Ly6G<sup>high</sup> monocytes [22, 23] and subsequently, weakened

---

**Figure 7.** Hypothetical scheme how intravenous MSC application modulates monocytes trafficking to the heart in viral myocarditis. MSC application abrogated the cardiac expression of the chemokines MCP-1, MCP-3 and CCL5, which attract pro-inflammatory monocytes, and lowered the levels of MCP-1 and MCP-3 in the circulation of CVB3-infected mice. In the heart, MSC application further reduced the expression of the adhesion molecules VCAM-1 and ICAM-1 in CVB3 mice. These effects led to diminished trafficking and homing of pro-inflammatory monocytes to the heart, as indicated by the reduced pro-inflammatory monocytes in the blood and heart, as well as the down-regulated expression of the pro-inflammatory cytokines IL-6, IL-12, and TNF-α and pro-fibrotic TGF-β in the heart of CVB3-infected mice. In parallel, MSC injection increased systemic levels of fractalkine, raising the deployment of anti-inflammatory monocytes to the heart. Finally, MSC retained the pro-inflammatory monocyte subsets in the spleen, preventing their mobilization, emigration to the blood and accumulation in the heart, limiting further immune-mediated cardiac injury and promoted spleen anti-inflammatory monocytes. Abbreviations: CCR2, chemokine (C-C motif) receptor-2; CVB3, coxsackievirus B3; CX3CL1, chemokine (C-X3-C motif) ligand-1; ICAM-1, intercellular adhesion molecule-1; IL, interleukin; MCP, monocyte chemotactic protein; MSC, mesenchymal stromal cell; TGF-β1, transforming growth factor-β1; TNF-α, tumor necrosis factor-α; VCAM-1, vascular cell adhesion molecule-1.
expression of pro-inflammatory cytokines in the failing myocardium. Prolonged exposure to inflammatory cytokines exacerbates adverse heart remodeling and enhances myocardial damage [52]. MSC abrogated the CVB3-induced expression of heart pro-inflammatory cytokines, which corresponded with a diminished presence of pro-inflammatory monocytes subsets in the heart of CVB3 MSC mice. Furthermore, LV expression of the pro-fibrotic cytokine TGF-B1 was significantly downregulated in CVB3 MSC mice in contrast to CVB3 mice. This finding is in line with our previous finding revealing the anti-fibrotic effect of MSC in a model of CVB3-induced viral myocarditis [15].

CONCLUSION

The present study demonstrates that MSC effectively attenuated myocardial inflammation via suppressing the cardiac infiltration of pro-inflammatory monocytes while promoting cardiac influx of anti-inflammatory monocytes. We suggest that MSC modulate monocytes trafficking via regulation of the cardiac and systemic chemokine expression pattern (Fig. 7). Hence, the present study gives deeper insights in how MSC regulate the mobilization and adhesion of monocyte subsets in a model of viral myocarditis. This provides new perspectives for the development of therapeutic strategies for inflammatory heart diseases via targeting the monocyte response to improve cardiac repair and healing.

ACKNOWLEDGMENTS

We like to acknowledge the assistance of the BCRT Flow Cytometry Lab and Annika Koschel, Kerstin Puhl, and Marzena Sosnowski (in alphabetical order) for excellent technical assistance. This study was supported by the Charité via a Lydia Rabinowitsch Stipendium to K.M.

AUTHOR CONTRIBUTIONS

K.M.: conception and design, administrative support, collection and/or assembly of data, data analysis and interpretation, manuscript writing; K.P., M.E.-S., and F.D.: collection and/or assembly of data; J.R.: provision of study material or patients; C.T.: financial support, provision of study material or patients, final approval of manuscript; S.V.L.: conception and design, administrative support, collection and/or assembly of data; data analysis and interpretation, manuscript writing.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

The authors indicate no potential conflicts of interest.

REFERENCES

1 Kindermann I, Kindermann M, Kandolf R et al. Predictors of outcome in patients with suspected myocarditis. Circulation 2008;118: 639–648.
2 Ismail MA, Hamid T, Bansal SS et al. Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: Critical importance of the cardioplessnic axis. Circ Res 2014;114:266–282.
3 Nahrendorf M, Swirski FK. Monocyte and macrophage heterogeneity in the heart. Circ Res 2013;112:1624–1633.
4 Nahrendorf M, Pittet M, Swirski FK. Monocytes: Protagonists of infant inflammation and repair after myocardial infarction. Circulation 2010;121:2437–2445.
5 Apostolakis S, Lip GY, Shantsila E. Monocytes in heart failure: Relationship to a deteriorating immune overreaction or a desperate attempt for tissue repair? Cardiovasc Res 2010;85:649–660.
6 Yang J, Zhang L, Yu C et al. Monocyte and macrophage differentiation: Circulation inflammatory monocyte as biomarker for inflammatory diseases. Biomark Res 2014;2:1.
7 Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354:610–621.
8 Swirski FK, Nahrendorf M, Etzrodt M et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009;325:612–616.
9 Leuschner F, Courtges G, Dutta P et al. Silencing of CCR2 in myocarditis. Eur Heart J 2015;36:1478–1488.
10 Tsou CL, Peters W, Si Y et al. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J Clin Invest 2007;117:902–909.
11 Nahrendorf M, Swirski FK, Akaiwa E et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007;204:3037–3047.
12 Karantalis V, Hare JM. Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res 2015;116:1413–1430.
13 Karantalis V, DiFede DL, Gerstenblith G et al. Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: The Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial. Circ Res 2014;114:1302–1310.
14 Mustaq M, DiFede DL, Golpanian S et al. Rationale and design of the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): A phase I/II, randomized pilot study of the comparative safety and efficacy of transcendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. J Cardiovasc Transl Res 2014;7:769–780.
15 Savvatis K, van Linthout S, Miteva K et al. Mesenchymal stromal cell injection delivery effects on Neomyogenesis in Dilated Cardiomyopathy (the POSEIDON-DCM study): A phase I/II, randomized pilot study of the comparative safety and efficacy of transcendocardial injection of autologous mesenchymal stem cell vs. allogeneic mesenchymal stem cells in patients with non-ischemic dilated cardiomyopathy. J Cardiovasc Transl Res 2014;7:769–780.
16 Van Linthout S, Savvatis K, Miteva K et al. Mesenchymal stem cells improve murine acute coxsackievirus B3-induced myocarditis. Eur Heart J 2011;32:2168–2178.
17 Maekawa Y, Anzai T, Yoshikawa T et al. Prognostic significance of peripheral monocytes after reperfused acute myocardial infarction: A possible role for left ventricular remodeling. J Am Coll Cardiol 2002;39:241–246.
18 BINGER T, STICH S, ANDREAS K et al. Migration potential and gene expression profile of human mesenchymal stem cells induced by CCL25. Exp Cell Res 2009;315:1468–1479.
19 Dutta P, Hoyer FF, Grigoryeva LS et al. Macrophages retain hematopoietic stem cells in the spleen via VCAM-1. J Exp Med 2015;212:497–512.
20 Lee JH, Wang C, Kim CH. FoxP3-regulatory T cells restrain splenic extramedullary myelopoiesis via suppression of hematopoietic cytokine-producing T cells. J Immunol 2009;183:6377–6386.
21 Shen Y, Xu W, Chu YW et al. Coxsackievirus group B type 3 infection upregulates expression of monocyte chemoattractant protein 1 in cardiac myocytes, which leads to enhanced migration of mononuclear cells in viral myocarditis. J Virol 2004;78:12548–12556.
22 Ghigo A, Franco I, Morello F et al. Myocyte signalling in leukocyte recruitment to the heart. Cardiovasc Res 2014;102:270–280.
23 Mestas J, Levy K. Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc Med 2008;18:228–232.
24 Serrina NV, Jia T, Hohl TM et al. Monocyte-mediated defense against microbial pathogens. Annu Rev Immunol 2008;26:421–452.
25 Barbalat R, Lau L, Locksley RM et al. Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands. Nat Immunol 2009;10:1200–1207.
26 Grainger JR, Wohlfert EA, Fuss LJ et al. Inflammatory monocytes regulate pathologic responses to commensals during acute gastrointestinal infection. Nat Med 2013;19:713–721.
enchymal stem cells in regenerative medicine indicates limited long-term engraftment and no ectopic tissue formations following mesenchymal stem cell therapy in humans. Curr Pharm Des 2011;17:269–275.

C. Miteva, P. Pappritz, E. El-Shafeey et al. Mesenchymal stromal cells: A promising cell source for the treatment of inflammatory diseases and patients enrollment. Eur Heart J 1995;16(suppl O):162–167.

J. Miteva, K. Miteva, V. Schultheiss HP et al. Mesenchymal stromal cells: A promising cell source for the treatment of inflammatory cardiomyopathy. Curr Pharm Des 2011;17:3295–3307.

J. Miteva, K. Miteva, V. Schultheiss HP et al. Mesenchymal stromal cells: Biological aspects and clinical applications. J Immunol Res 2015;2015:394917.

J. Miteva, K. Miteva, V. Schultheiss HP et al. Mesenchymal stromal cells: A promising cell source for the treatment of inflammatory cardiomyopathy. Curr Pharm Des 2011;17:3295–3307.

J. Miteva, K. Miteva, V. Schultheiss HP et al. Mesenchymal stromal cells: A promising cell source for the treatment of inflammatory cardiomyopathy. Curr Pharm Des 2011;17:3295–3307.